Milton Essex boosts Sanford Biotech capital to drive advanced mastitis cell therapy

MILTON ESSEX S.A. ( (PL:MTN) ) just unveiled an announcement. Milton Essex S.A., acting as sole shareholder of Sanford Biotech, has approved a PLN 400,400 share capital increase at its Warsaw-based subsidiary, lifting capital to PLN 408,100 while retaining 100% ownership. Nearly all of the new funds, PLN 398,000, will finance research and development of the advanced veterinary cell therapy VET-ATMP (SB-REG-KMAS) for treating mastitis in dairy cows, with the remainder covering corporate costs tied to the capital change. The injection of capital advances one of the declared uses of proceeds from Milton Essex's series N share issue and marks another stage in the SB-REG-KMAS program, implemented with strategic partner HISTOCELL S.L. in Spain. The funding will support scaling mesenchymal stem cell production, GMP-compliant manufacturing, preclinical studies including Target Animal Safety tests, and regulatory preparations for planned clinical trials, underscoring the program's strategic role in building the group's veterinary medicines portfolio. More about MILTON ESSEX S.A. Milton Essex S.A., based in Warsaw, operates through its subsidiary Sanford Biotech Sp. z o.o. in the veterinary pharmaceuticals and advanced cell-therapy segment. The group focuses on developing innovative veterinary medicinal products, including advanced therapy medicinal products (ATMPs) for livestock, with a particular emphasis on mastitis treatment in dairy cows, in partnership with European biotech firm HISTOCELL S.L. Average Trading Volume: 45,529 Technical Sentiment Signal: Sell Current Market Cap: PLN48.07M Find detailed analytics on MTN stock on TipRanks' Stock Analysis page. This story was written using TipRanks's AI tools and reviewed by a TipRanks editor. Disclaimer & DisclosureReport an Issue